Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Feb 11, 2025
Data Byte

FDA’s new and supplemental approvals in January

Vertex’s Nav1.8 inhibitor, Axsome’s acute migraine therapy and Daiichi-AZ’s two ADCs for breast cancer among the month’s approvals
BioCentury | Jan 8, 2025
Data Byte

Seven PDUFA dates on FDA’s January agenda

Decisions include Ozempic for CKD, a non-opioid painkiller, AZ-Daiichi’s TROP2 ADC, and an allogeneic T cell therapy
BioCentury | Oct 3, 2024
Discovery & Translation

Type 2 cytokines for durable cancer remission, drugging GTPases: BioCentury’s Science Spotlight

BioCentury’s roundup of translational innovations
BioCentury | Oct 1, 2024
Data Byte

Five PDUFA dates on FDA’s October agenda

Decisions include Opdivo as perioperative therapy for NSCLC, and a Lumakras combination for mCRC
BioCentury | Sep 18, 2024
Product Development

View from ESMO: iTeos data keep TIGIT alive, for now

Plus readouts from Genmab, AstraZeneca, Merck, Astellas and more
BioCentury | Sep 6, 2024
Distillery Therapeutics

Peptide blockade of YTHDF3 palmitoylation for pancreatic cancer

BioCentury | Aug 24, 2024
Deals

Pharma deals pivot from high-risk modalities, targets

BioCentury’s analysis of 12 months of dealmaking between biotechs and top pharmas
BioCentury | Jul 26, 2024
Finance

Public Equity Report: Palvella lands on NASDAQ via Pieris merger

Plus: Verastem’s follow-on and Hangzhou Jiuyuan’s IPO plans
BioCentury | Jul 23, 2024
Data Byte

Accelerated approvals of Epkinly, Augtyro, Krazati among FDA’s June label expansions

The month also brought conversions to full approval for Retevmo and Sirturo
Items per page:
1 - 10 of 788